PDCD1 and cancer: This research indicated that on account of ASCO-VF and ESMO-MCBS frameworks, no correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors was present in treating malignant tumors, and the same results were observed in subgroups stratified by drugs or indications.